X0306 4 2016-02-01 0 0001510580 Kite Pharma, Inc. KITE 0001609642 Better Marc C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404 0 1 0 0 VP, Product Sciences Common Stock 2016-02-01 4 M 0 9000 0.38 A 16688 D Common Stock 2016-02-01 4 S 0 2499 46.50 D 14189 D Common Stock 2016-02-01 4 S 0 4938 47.38 D 9251 D Common Stock 2016-02-01 4 S 0 1410 48.47 D 7841 D Common Stock 2016-02-01 4 S 0 153 49.20 D 7688 D Employee Stock Option (Right to Buy) 0.38 2016-02-01 4 M 0 9000 0.00 D 2023-01-15 Common Stock 9000 60000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.92 to $46.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.93 to $47.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.03 to $48.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the stock option vested and became exercisable on January 2, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. /s/ Dave Tanen, Attorney-in-Fact 2016-02-03